Incorporating novel agents in the treatment of myelodysplastic syndromes
To access this article, please choose from the options below
PII: S0145-2126(09)00366-X
doi:10.1016/j.leukres.2009.07.021
© 2009 Elsevier Ltd. All rights reserved.
PII: S0145-2126(09)00366-X
doi:10.1016/j.leukres.2009.07.021
© 2009 Elsevier Ltd. All rights reserved.